More News! Cancer therapies, trial failures, bankruptcy and more…

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of European biotech news that didn’t quite make the cut over the last week or so.

Clinical trials

  • Autolus Therapeutics announced promising safety results from the ongoing phase I study of its CAR T-cell therapy.
  • Swiss medical device company Novostia raised €5.7M to start first clinical trials of its heart valve prosthesis.
  • Follow on data from a phase III trial of Swiss biotech Santhera’s drug idebenone shows it slows the loss of lung function in patients with the genetic disease Duchenne muscular dystrophy by 50% per year.
  • German biotech Medigene treated the first patient in its phase I/II trial of its T-cell receptor modified T cell therapy for a number of different blood cancers.
  • French biotech Theranexus released disappointing preliminary results from the phase II trial of its narcolepsy candidate drug, showing no significant improvements over standard therapy.
  • A UK-based trial of a therapy derived from nerve cells for treatment of Parkinson’s disease appeared to repair brain cells involved in the condition, but had no significant impact on patient symptoms.


  • Scottish biotech TC Biopharm will collaborate with Trinity College in Dublin to speed up development of its gamma-delta T cell banks for treating solid tumors. Initial clinical trials of the treatments are planned for later this year.
  • Roche and Immatics are collaborating to test the safety and effectiveness of the German biotech’s anti-cancer cell therapy in combination with Roche’s antibody-based drug atezolizumab for treatment of solid tumors.

Regulations and funding

  • Themis Bioscience, an Austrian biotech focusing on infectious diseases and cancer, received fast track designation from the US FDA for its Chikungunya vaccine candidate.
  • Austrian biotech Marinomed will receive €15M in funding from the European Investment Bank to continue to develop its innovative allergy, respiratory and eye disease therapies.
  • Samsara Therapeutics, a European biotech developing anti-aging therapies, has received undisclosed seed funding from Apollo Ventures, a VC also focusing on age-related disease. The VC is also helping the company build its scientific team.
  • Biocartis’ DNA mismatch repair diagnostic for testing of colorectal cancer tumors has received a CE mark, allowing it to be marketed alongside the Belgian company’s existing colorectal cancer test.
  • FIT Biotech, a listed Finnish biotech focusing on gene therapy vectors, filed for bankruptcy after its key funder Alpha Blue Ocean failed to pay the company the €500,000 it owed them under an earlier financing agreement.


Images via E. Resko

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.